Guardant Health Inc

Company Profile

• Business description

  Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

• Contact

  3100 Hanover Street
  Palo AltoCA94304
  USA

  T: +1 855 698-8887

  E: [email protected]

  https://www.guardanthealth.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Diagnostics & Research

  Fiscal Year End

  31 December 2025

  Employees

  2,021